All Stories

  1. Antitumor immuno-virotherapy with attenuated strains of measles virus

    Article • Virologie, August 2025, John Libbey Eurotext

    Dr Jean-Francois Fonteneau

  2. Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity

    Article • Molecular Therapy Oncology, December 2024, Elsevier

    Dr Jean-Francois Fonteneau

  3. CRCI2NA inaugural symposium: A meeting on tumor and immune ecosystems

    Article • Biology of the Cell, November 2024, Wiley

    Dr Jean-Francois Fonteneau

  4. Loss of miR-200c-3p promotes resistance to radiation therapy via the DNA repair pathway in prostate cancer

    Article • Cell Death and Disease, October 2024, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  5. Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment

    Article • OncoImmunology, July 2024, Taylor & Francis

    Dr Jean-Francois Fonteneau

  6. Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy

    Article • Respiratory Research, April 2024, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  7. TP53 mutations correlate with the non‐coding RNA content of small extracellular vesicles in melanoma

    Article • Journal of Extracellular Biology, July 2023, Wiley

    Dr Jean-Francois Fonteneau

  8. Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells

    Article • Medical Oncology, July 2023, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  9. Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma

    Article • JTO Clinical and Research Reports, December 2022, Elsevier

    Dr Jean-Francois Fonteneau

  10. Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment

    Article • Molecular Oncology, October 2022, Wiley

    Dr Jean-Francois Fonteneau

  11. Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathways

    Article • Stem Cell Research & Therapy, January 2022, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  12. STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact

    Article • Cells, November 2021, MDPI AG

    Dr Jean-Francois Fonteneau

  13. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy

    Article • Frontiers in Oncology, June 2021, Frontiers

    Dr Jean-Francois Fonteneau

  14. Endogenous retrovirus expression activates type-I interferon signaling in an experimental mouse model of mesothelioma development

    Article • Cancer Letters, June 2021, Elsevier

    Dr Jean-Francois Fonteneau

  15. Le vaccin contre la fièvre jaune : un nouveau traitement anti-tumoral ?

    Article • médecine/sciences, December 2020, EDP Sciences

    Dr Jean-Francois Fonteneau

  16. High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma

    Article • Molecular Therapy — Oncolytics, September 2020, Elsevier

    Dr Jean-Francois Fonteneau

  17. Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma

    Article • Journal of Thoracic Oncology, July 2020, Elsevier

    Dr Jean-Francois Fonteneau

  18. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma

    Article • Journal for ImmunoTherapy of Cancer, June 2020, BMJ

    Dr Jean-Francois Fonteneau

  19. Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus

    Article • Journal of Thoracic Oncology, May 2020, Elsevier

    Dr Jean-Francois Fonteneau

  20. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma

    Article • Cancer Letters, March 2020, Elsevier

    Dr Jean-Francois Fonteneau

  21. MicroRNAs in Tumor Exosomes Drive Immune Escape in Melanoma

    Article • Cancer Immunology Research, December 2019, American Association for Cancer Research (AACR)

    Dr Jean-Francois Fonteneau

  22. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death

    Article • September 2019, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  23. p53 regulates CD46 expression and measles virus infection in myeloma cells

    Article • Blood Advances, December 2018, American Society of Hematology

    Dr Jean-Francois Fonteneau

  24. Abstract 1002: Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1

    Article • Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Dr Jean-Francois Fonteneau

  25. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1

    Article • Oral Oncology, July 2018, Elsevier

    Dr Jean-Francois Fonteneau

  26. Oncolytic viruses sensitize human tumor cells for NY-ESO-1 tumor antigen recognition by CD4+ effector T cells.

    Article • OncoImmunology, December 2017, Taylor & Francis

    Nathalie Labarriere, Dr Frederic Tangy, Dr Jean-Francois Fonteneau, Mathieu Crupi

  27. Viral cancer therapies: are they ready for combination with other immunotherapies?

    Article • Future Oncology, August 2017, Future Medicine

    Dr Jean-Francois Fonteneau

  28. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers

    Article • Journal of Autoimmunity, July 2017, Elsevier

    Dr Jean-Francois Fonteneau

  29. Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus

    Article • Current Gene Therapy, March 2017, Bentham Science Publishers

    Dr Jean-Francois Fonteneau

  30. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells

    Article • OncoImmunology, November 2016, Taylor & Francis

    Dr Jean-Francois Fonteneau

  31. Pleural Effusions from Patients with Mesothelioma Induce Recruitment of Monocytes and Their Differentiation into M2 Macrophages

    Article • Journal of Thoracic Oncology, October 2016, Elsevier

    Dr Jean-Francois Fonteneau

  32. The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+T Cells after Intercellular Antigen Transfer

    Article • The Journal of Immunology, November 2015, The American Association of Immunologists

    Dr Jean-Francois Fonteneau

  33. Oncolytic virotherapy for human malignant mesothelioma: recent advances

    Article • Oncolytic Virotherapy, September 2015, Dove Medical Press

    Dr Frederic Tangy, Dr Jean-Francois Fonteneau

  34. Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine

    Article • Oncotarget, November 2014, Impact Journals, LLC

    Dr Jean-Francois Fonteneau

  35. Sensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response

    Article • Oncotarget, November 2014, Impact Journals, LLC

    Dr Jean-Francois Fonteneau

  36. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells

    Article • International Journal of Cancer, August 2014, Wiley

    Dr Jean-Francois Fonteneau

  37. A Spliced Antigenic Peptide Comprising a Single Spliced Amino Acid Is Produced in the Proteasome by Reverse Splicing of a Longer Peptide Fragment followed by Trimming

    Article • The Journal of Immunology, January 2014, The American Association of Immunologists

    Dr Jean-Francois Fonteneau

  38. Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy

    Article • Immunotherapy, June 2013, Future Medicine

    Dr Jean-Francois Fonteneau

  39. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells

    Article • OncoImmunology, May 2013, Taylor & Francis

    Dr Jean-Francois Fonteneau

  40. Antitumor Virotherapy by Attenuated Measles Virus (MV)

    Article • Biology, March 2013, MDPI AG

    Dr Frederic Tangy, Dr Jean-Francois Fonteneau

  41. Measles Virus Vaccine-Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells

    Article • Clinical Cancer Research, January 2013, American Association for Cancer Research (AACR)

    Dr Jean-Francois Fonteneau

  42. MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge

    Article • BioMed Research International, January 2013, Hindawi Publishing Corporation

    Dr Jean-Francois Fonteneau

  43. Natural Oncolytic Activity of Live-Attenuated Measles Virus against Human Lung and Colorectal Adenocarcinomas

    Article • BioMed Research International, January 2013, Hindawi Publishing Corporation

    Dr Jean-Francois Fonteneau

  44. Purification of circulating plasmacytoid dendritic cells using counterflow centrifugal elutriation and immunomagnetic beads

    Article • Cytotherapy, August 2012, Elsevier

    Dr Jean-Francois Fonteneau

  45. Downregulation of MUC1 expression and its recognition by CD8+ T cells on the surface of malignant pleural mesothelioma cells treated with HDACi

    Article • European Journal of Immunology, January 2012, Wiley

    Dr Jean-Francois Fonteneau

  46. Human dendritic cells sequentially matured with CD4+ T cells as a secondary signal favor CTL and long-term T memory cell responses

    Article • Biological Research, January 2012, SciELO Comision Nacional de Investigacion Cientifica Y Tecnologica (CONICYT)

    Dr Jean-Francois Fonteneau

  47. Vaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growth

    Article • Vaccine, July 2011, Elsevier

    Dr Jean-Francois Fonteneau

  48. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma

    Article • European Respiratory Journal, May 2011, European Respiratory Society (ERS)

    Dr Jean-Francois Fonteneau

  49. Recognition of pleural mesothelioma by mucin-1(950-958)/human leukocyte antigen A*0201-specific CD8+ T-cells

    Article • European Respiratory Journal, May 2011, European Respiratory Society (ERS)

    Dr Jean-Francois Fonteneau

  50. Dendritic cell preparation for immunotherapeutic interventions

    Article • Immunotherapy, March 2009, Future Medicine

    Dr Jean-Francois Fonteneau

  51. A HLA-Cw*0701 restricted Melan-A/MART1 epitope presented by melanoma tumor cells to CD8+ tumor infiltrating lymphocytes

    Article • Medical Oncology, December 2007, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  52. Synthesis of Glycocluster−Tumor Antigenic Peptide Conjugates for Dendritic Cell Targeting

    Article • Bioconjugate Chemistry, September 2007, American Chemical Society (ACS)

    Dr Jean-Francois Fonteneau

  53. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes

    Article • Medical Oncology, February 2007, Springer Science + Business Media

    Dr Jean-Francois Fonteneau

  54. Dendritic Cells Expand Epstein Barr Virus Specific CD8+ T Cell Responses More Efficiently Than EBV Transformed B Cells

    Article • Human Immunology, September 2005, Elsevier

    Dr Jean-Francois Fonteneau

  55. Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells

    Article • Journal of Virology, May 2004, ASM Journals

    Dr Jean-Francois Fonteneau

  56. Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells

    Article • Blood, December 2003, American Society of Hematology

    Dr Timothy L Cover, Dr Jean-Francois Fonteneau

  57. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity

    Article • Blood, January 2003, American Society of Hematology

    Dr Jean-Francois Fonteneau

  58. A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy

    Article • Vaccine, December 2002, Elsevier

    Dr Jean-Francois Fonteneau

  59. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses

    Article • Current Opinion in Immunology, August 2002, Elsevier

    Dr Jean-Francois Fonteneau

  60. Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus

    Article • AIDS, July 2002, Wolters Kluwer Health

    Dr Jean-Francois Fonteneau

  61. Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells

    Article • AIDS, January 2002, Wolters Kluwer Health

    Dr Jean-Francois Fonteneau

  62. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells

    Article • European Journal of Immunology, December 2001, Wiley

    Dr Jean-Francois Fonteneau

  63. Generation of high quantities of viral and tumor-specific human CD4+ and CD8+ T-cell clones using peptide pulsed mature dendritic cells

    Article • Journal of Immunological Methods, December 2001, Elsevier

    Dr Jean-Francois Fonteneau

  64. Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells

    Article • The Journal of Immunology, November 2001, The American Association of Immunologists

    Dr Jean-Francois Fonteneau

  65. Dendritic Cell–Dead Cell Interactions: Implications and Relevance for Immunotherapy

    Article • Journal of Immunotherapy, July 2001, Wolters Kluwer Health

    Dr Jean-Francois Fonteneau

  66. Dendritic cells resurrect antigens from dead cells

    Article • Trends in Immunology, March 2001, Elsevier

    Dr Jean-Francois Fonteneau

  67. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function

    Article • Journal of Clinical Investigation, January 2001, American Society for Clinical Investigation

    Dr Jean-Francois Fonteneau

  68. Requirement of Mature Dendritic Cells for Efficient Activation of Influenza A-Specific Memory CD8+ T Cells

    Article • The Journal of Immunology, August 2000, The American Association of Immunologists

    Dr Jean-Francois Fonteneau

  69. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues

    Article • International Immunology, December 1999, Oxford University Press (OUP)

    Dr Jean-Francois Fonteneau

  70. LFA-3 co-stimulates cytokine secretion by cytotoxic T lymphocytes by providing a TCR-independent activation signal

    Article • European Journal of Immunology, April 1998, Wiley

    Dr Jean-Francois Fonteneau